Heisoog Kim1,2, Ciprian Catana2, Eva-Maria Ratai2, Wei-Ting Zhang2, Priscilla Yeo2, Ovidiu Cristian Andronesi2, Tracy T. Batchelor3, Rakesh K. Jain4, A. Gregory Sorensen2
1NSE/HST, Massachusetts Institute of Technology, Cambridge, MA, USA; 2Radiology, Massachusetts General Hospital, Boston, MA, USA; 3Neurology, Massachusetts General Hospital, Boston, MA, USA; 4Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
This study evaluated the predominant metabolites changes in 1H-MRS to provide supplementary information understanding the response of cancerous tissue to the anti-angiogenic agent in patients with recurrent malignant glioblastoma. After one dose, NAA/norCre and Cho/norCre in eleven positive-responding patients showed a significant increase in ET. Also, NAA/norCre and Cho/norCre measured in all twenty patients showed significant changes at day 28, and at day 112, the trend was reversed, an increase of Cho and a decrease of NAA. By evaluating the early changes in the predominant metabolites, it would reveal a pharmacologic effect of cedrinib.